Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Csl - The Real Truth

Why Australia is right to put affordable medicine ahead of beating US pharmaceutical tariffs

From July 31, the United States will impose up to 100% tariffs on pharmaceuticals coming into the US. Some Australian-made exports look set to pay that highest rate, while some other countries – including the UK, Japan and the European Union – have negotiated lower rates.

The Conversation

CSL, Mayne Pharma expect to dodge new US pharma tariffs

CSL, Mayne Pharma expect to dodge new US pharma tariffs

Both CSL and Adelaide-based woman's health company Mayne Pharma say they won't be impacted by Donald Trump's new pharmaceutical tariffs.

Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US

Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US

Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Australia backs cheaper medicines in face of US levies

The government says it won't back down or negotiate the pharmaceutical benefits scheme despite pressure from the Trump administration following new tariffs.

Australian shares bounce on talk of Iran war slowdown

Hopes of potential de-escalation in the Middle East and US assurances around crude supply have supported a lift in equities, despite a fresh wave of attacks.

Biotech giant's shares dive after CEO's shock departure

Shares in Australia's largest biopharmaceutical company have hit an eight-year low after the sudden retirement of its chief executive.

'Didn't have the skills': biotech boss retires abruptly

A desire for new leadership has been cited as a reason for the sudden retirement of the head of an $89 billion biopharmaceutical company.

inkl

Read news from The Economist, FT, and more,
with one subscription

Konstantin Grigorishin: Why Team-Based Formats Resonate with Modern Sports Fans

Konstantin Grigorishin: Why Team-Based Formats Resonate with Modern Sports Fans

Sport has always been about more than results. At its core, fan engagement is shaped by emotional connection, identity, and continuity over time.

Australian shares slip as energy, IT stocks fall

Australian shares slip as energy, IT stocks fall

Energy and IT stocks have led the bourse lower in 2025's third-last trading session, anchored by weakness in the heavyweight financials and materials sectors.

CSL injects $2.3b into US for valuable blood plasma

CSL injects $2.3b into US for valuable blood plasma

After Donald Trump threatened pharmaceutical tariffs, CSL says it will invest another $2.3 billion building a new blood plasma facility in the United States.

Australians are boozing less, getting fewer flu jabs and choosing home brands: five things we learned from AGM season

Australians are boozing less, getting fewer flu jabs and choosing home brands: five things we learned from AGM season

Companies offer some surprising insights into changing consumer trends at annual shareholder meetings

The Guardian - AU

Deposit return scheme blocked after issue became ‘politicised’, court told

Deposit return scheme blocked after issue became ‘politicised’, court told

Waste management firm Biffa is suing the Scottish Government for £51.4 million, following the decision to delay the proposed scheme.

Evening Standard

Government assurances on deposit return ‘foundational’ to investment, says Biffa

Government assurances on deposit return ‘foundational’ to investment, says Biffa

The waste management firm is suing the Scottish Government for £51.4 million after the recycling initiative was delayed.

Evening Standard

CSL share price plummets amid shareholder revolt over executive pay plans

CSL share price plummets amid shareholder revolt over executive pay plans

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

CSL shares plunge to six-year low as growth stalls

CSL shares have tumbled more than 15 per cent to their lowest level since 2018 after it cut its profit forecast given falling US flu vaccine rates.

Aussie shares fall as miners, major companies drag

A strong banking sector performance wasn't enough to rescue Australia's share market from a negative session, as miners and two segment leaders tumbled.

The Guardian - AU

Australian executives don’t deserve big bonuses. It’s time to end the cult of the CEO

Hardly anyone now believes in the neoliberal myth that giving more money to already highly paid executives leads to better companies

The Guardian - AU

CSL and Optus pay millions to executives despite paying no company tax in Australia

Biotech company argues high pay is required to retain and attract ‘world-class’ talent

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - AU

Optus among companies earning billions in Australia but paying no income tax

Latest ATO report reveals string of mostly multinational firms continue to be able to pay no or very little income tax, including Netflix, Apple and Microsoft

Australia to cop deeper impact from new US meds tariffs

The US plan to slap new tariffs on pharmaceutical drugs will likely have a chilling effect on Australia's pharmaceutical export sector, a think tank says.

Aussie pharma giant sees no pain from big Trump tariffs

The Australian government and pharmaceutical exporters are scrambling to determine whether they will be impacted by Donald Trump's latest tariff bombshell.

Aussie shares follow Wall Street to finish in the green

Anticipation of rate cuts in the Unites States has buoyed Wall Street traders, with the positive outlook flowing onto the Australian share market.

CSL in $757m deal with pioneering Dutch biotech

CSL is paying to partner with a Dutch company developing an emergency treatment for patients on blood thinners who experience uncontrolled bleeding.

Aussie stocks down as September sell-down continues

Australian shares have begun the week lower, led by banks and energy stocks as gold hovers near record highs.

Biotech giant to slash 3000 jobs, spin-off vaccine arm

Pharmaceutical giant CSL has announced a major shake-up for its vaccination arm and for jobs as the company aims to cut costs.

1 2 3 4

People

182,313 stories

Roddy Dunlop KC

Stephen Duckett

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the White House

Scottish Government

the Scottish Government

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

363,403 stories

136,648 stories

The United States

the European Union

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play